Zenas BioPharma ZBIO 深 沪
等待开盘 08-17 09:30:00 美东时间
29.51
+0.310
+1.06%
华盛通- 最 高30.31
- 今 开28.76
- 成交量 63.00万股
- 最 低 28.163
- 昨 收 29.20
- 总市值 18.63亿
- 52周最高 44.60
- 市盈率 静 --
- 换手率 1.00%
- 52周最低 13.50
- 委 比 97.87%
- 总股本 6313.34万
- 历史最高 44.60
- 量 比 1.02
- 振 幅 7.35%
- 历史最低 5.83
- 每 手 1
- 风险率 6.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
今天 13:37
Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target
Wedbush analyst Martin Fan reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Outperform and maintains $45 price target.
08-14 21:07
Zenas BioPharma Q2 EPS $(1.77) Misses $(1.08) Estimate, Sales $1.000M Miss $18.750M Estimate
Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.77) per share which missed the analyst consensus estimate of $(1.08) by 63.89 percent. This is a 41.6 percent decrease over losses of $(1.25) per share from the same period last year. The company reported quarterly sales of $1.000 millio...
08-13 19:24
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Zenas BioPharma reported financial results for Q2 2026 and provided updates on its pipeline. The FDA accepted the BLA for obexelimab to treat IgG4-RD with a PDUFA date of May 27, 2027. New bioequivalence data for obexelimab's delivery methods were confirmed. Phase 2 SunStone SLE trial results are expected in Q4 2026. ZB021's Phase 1 trial is ongoing, with initial data anticipated by year-end. Four abstracts for orelabrutinib were accepted for MST...
08-13 11:00
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., July 17, 2026 – Zenas BioPharma, Inc. granted stock options and restricted stock units to newly hired employees as inducement grants under Nasdaq Listing Rule 5635(c)(4). The Stock Options, totaling 35,750 shares with an exercise price of $29.41, vest over four years. The RSUs, totaling 79,050 units, vest in four equal installments annually. Both grants are subject to continued employment and governed by the Company’s 2026 Inducem...
07-17 20:15
Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 300 points on Friday. Shares of Lennar Corp (NYSE:LEN) fell sharply in pre-market trading after the company posted mixed second-quarter results. Lennar reported quarterly adjusted earnings of $1.31 per share, which beat...
06-12 20:02
Zenas BioPharma Submits An FDA Biologics License Application For Obexelimab In Immunoglobulin G4-Related Disease
IgG4-RD is a debilitating chronic fibro-inflammatory disease affecting multiple organ systems, often resulting in irreversible tissue damage and organ failure. Obexelimab, an investigational therapy, is a bifunctional
05-28 19:14
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
